Prevenar 13
Details for Prevenar 13 vaccine and its components.
Sponsor:
Pfizer Australia
Administration route:
Intramuscular injection
Vaccine group:
Pneumococcal conjugate vaccine
Registered for use in children aged ≥6 weeks and in adults.
13vPCV — 13-valent pneumococcal conjugate vaccine
Each 0.5 mL monodose pre-filled syringe contains:
- 2.2 µg each of pneumococcal capsular polysaccharide of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F
- 4.4 µg of pneumococcal capsular polysaccharide of serotype 6B
- succinic acid
- polysorbate 80
Antigens are conjugated to non-toxic Corynebacterium diphtheriae CRM197 protein and adsorbed onto 0.565 mg aluminium phosphate.
For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.
Page history
Last updated:
4 June 2018
Last reviewed:
4 June 2018
Definitions
- 13vPCV
- 13-valent pneumococcal conjugate vaccine
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/prevenar-13.